ZUMA-2 3-Year Follow-Up | Hackensack Meridian Health   

John Theurer Cancer Center at Hackensack University Medical Center Researchers Co-Author ZUMA-2 Three-Year Follow-Up on CAR T-Cell for Mantle Cell Lymphoma

Longest follow-up of CAR T-Cell in MCL to date showed long-term benefits for patients

Three Year Follow Up

CART cell brexu-cel is the first approved cell therapy in MCL after 1 line of therapy and a game changer based on ORR of 91% and 68% CR.

Researchers with John Theurer Cancer Center at Hackensack University Medical Center contributed to a 3-year follow-up ZUMA-2 study of brexucabtagene autoleucel (KTE-X19) autologous anti-CD19 chimeric antigen receptor (CAR) T-Cell therapy in patients with relapsed/refractory mantle cell lymphoma, including high-risk subgroups in the ZUMA-2 Study. Here are a few key points of the research, which was published in the Journal of Clinical Oncology:

  • This study is the longest follow-up of CAR T-Cell therapy in patients with MCL to date with at 3y 75% of the initial CR still durable, and very few late relapses (only 3 past 24 months) and overall close to 40% of the treated population likely cured.
  • High-peak CAR T-Cell expansion in responders correlates with superior outcome and negative MRD at 3 and 6 months.
  • Patients with high-risk features had similar response rates while patients with prior bendamustine (within 6 months) might have less CART expansion and worse outcome.

The study reviewed outcomes of a 3-year follow-up in the ZUMA-2 study of KTE-X19 in relapsed/refractory MCL, including for subgroups by prior therapy (bendamustine and type of Bruton tyrosine kinase inhibitor [BTKi]) or high-risk characteristics, after a single infusion of KTE-X19. The objective response rate among the 68 treated patients was 91%, with 68% complete responses.

Learn more about innovative cancer treatments at John Theurer Cancer Center at Hackensack University Medical Center.

Best Regional Hospitals
We use cookies to improve your experience. Please read our Privacy Policy or click Accept.